|
 |
Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R. Holland AM, Grubin J, Cabrera-Perez J, Brentjens
RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Liu C, van den Brink MRM. Off-
the-shelf immunotherapy using allogeneic T cell precursors. Nature Biotechnology. 2008 Apr;26(4):453-61. Epub 2008
Mar 30.
Kim TD, Terwey TH, Zakrzewski JL, Suh D, Kochman AA, Chen ME, King CG, Borsotti C, Grubin J, Smith OM, Heller G, Liu C, Murphy GF, Alpdogan O, van den Brink MR. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood 2008; 111:2929-2940
Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Alpdogan O, van den Brink MRM. IFNγ and FasL are required for graft-versus-tumor activity against renal cell carcinoma in the absence of graft-versus-host disease. Journal of Immunology 2007; 179:1669-1680.
Borsotti C, Franklin ARK, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MRM. Absence of donor T cell-derived soluble TNF decreases graft-versus-host-disease without impairing graft-versus-tumor activity. Blood 2007; 110:783-786.
Meada T, Merghoub T, Hobbs RM, Dong L, Meada M, Zakrzewski J, van den Brink MRM, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, Pandolfi PP. LRF regulates B versus T lymphoid lineage fate decision by opposing Notch signaling. Science 2007; 316:860-866.
Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Cabrera-Perez J, Radhakrishnan R, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MRM. Adoptive transfer of in vitro generated T cell precursors enhances donor T cell reconstitution in allogeneic hematopoietic stem cell transplantation recipients. Nature Medicine 2006; 12:1039-1047.
Perales M-A, Diab A, Cohen AD, Huggins DW, Guevara-Patino JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MRM. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. Journal of Immunology 2006; 177:4159-4167.
Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Hubbard VM, Kochman AA, Lu SX, Miles RC, Sakaguchi S, Houghton AN, van den Brink MRM. GITR Activation Breaks Self-Tolerance to Melanoma Differentiation Antigens and Enhances Anti-Tumor Immunity. Journal of Immunology 2006; 176:6434-6442.
Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, Alpdogan O, van den Brink M, Bertino JR, Blasberg RG, Banerjee D, Gelovani J. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplant 2006; 15:75-82.
Alpdogan O, Hubbard VM, Smith OM, Goldberg GL, Gray DH, Lu S, Kochman AA, Eng JM, Muriglan SJ, Boyd RL, van den Brink MRM. Keratinocyte growth factor (KGF) is required for post-natal thymic regeneration. Blood 2006; 107:2453-2460.
Waldman E, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Lu SX, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MRM. Absence of the β7 integrin results in less graft-versus-host disease due to decreased homing of alloreactive T cells to the intestine. Blood 2006; 107:1703-1711.
Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu SX, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MRM. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005; 106:3322-3330.
Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MRM. Absence of inducible costimulator on alloreactive T cells reduces graft-versus-host disease and induces Th2 deviation. Blood 2005; 106:3285-3292.
Muriglan SJ, Ramirez-Montagut T, Alpdogan O, van Huystee TW, Eng JM, Hubbard VM, Kochman AA, Tjoe KH, Riccardi C, Pandolfi PP, Sakaguchi S, Houghton AN, van den Brink MRM. GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-versus-Host Disease. Journal of Experimental Medicine 2004; 200:149-157.
Alpdogan O, Schmaltz C, Muriglan SJ, Doubrovina E, Schiro R, Kappel BJ, Greenberg AS, Willis LM, Rotolo JA, O'Reilly RJ, van den Brink MRM. Insulin Growth Factor-I (IGF-I) enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation 2003; 75: 1977-1983.
Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MRM. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101:2440-2445.
Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon J, van den Brink MRM. T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine 2002; 8:1433-37.
|
|
|
|
